Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long‐term follow‐up of the Nordic Lymphoma Group MCL6 Philemon trial

Abstract Relapsed or refractory mantle cell lymphoma (R/R MCL) remains difficult to treat, with outcomes dependent on the treatment regimen and remission duration after first‐line therapy. Several non‐chemotherapeutic regimens are under evaluation in R/R, but few studies report long‐term outcomes. I...

Full description

Bibliographic Details

Published in:	HemaSphere
Main Authors:	Elin Forsgren, Rasmus R. K. Jørgensen, Hans Bentzen, Jon Riise, Jacob Haaber, Annika Pasanen, Hanne Kuitunen, Karin F. Wader, Tarec C. El‐Galaly, Martin Hutchings, Ingrid Glimelius, Mats Jerkeman
Format:	Article
Language:	English
Published:	Wiley 2025-03-01
Online Access:	https://doi.org/10.1002/hem3.70101